The FDA, friday, approved a new injectable treatment for age-related macular degeneration, or AMD.
The drug, Lucentis (ranbizumab), produced by Genentech and Novartis, treats the wet form of the disease. The wet form, while less common, is more destructive than the more common dry form.
Lucentis is injected into eyes up to five times a year. After twelve months, patients showed significant increase in vision, as opposed to other treatments, which just halt the disease’s progression.
